Retrospective Cohort Study
Copyright ©The Author(s) 2019.
World J Gastrointest Endosc. Feb 16, 2019; 11(2): 133-144
Published online Feb 16, 2019. doi: 10.4253/wjge.v11.i2.133
Table 4 Multivariable analysis of use of endoscopic retrograde cholangiopancreatography
Adjusted OR of receiving ERCP (95%CI)
Sex
Male1.00 (REF)
Female1.03 (0.96-1.11)
Age
65-751.00 (REF)
76+0.88 (0.82-0.95)
Marital status
Married1.00 (REF)
Not married0.90 (0.85-0.97)
Race
White1.00 (REF)
Black0.92 (0.82-1.04)
Other0.83 (0.70-0.97)
Education (zip code)
> 50% high school only1.14 (1.04-1.24)
> 50% some college1.00 (REF)
Income (zip code)
< 75th percentile1.10 (1.00-1.20)
> 75th percentile1.00 (REF)
Year of diagnosis
2000-20031.00 (REF)
2004-20070.85 (0.78-0.92)
2008-20110.76 (0.70-0.83)
Metropolitan area
Metropolitan area1.00 (REF)
Non-metropolitan area0.87 (0.79-0.97)
United States region
Southeast1.00 (REF)
Northeast1.07 (0.96-1.20)
Midwest0.96 (0.86-1.09)
West Coast1.03 (0.93-1.13)
Comorbid conditions
Charlson score 01.00 (REF)
Charlson score 11.06 (0.98-1.15)
Charlson score 20.96 (0.86-1.07)
Charlson score 3+0.99 (0.88-1.11)
Cancer site
Body or tail1.00 (REF)
Head of the Pancreas3.27 (2.99-3.57)
Symptoms1
Jaundice7.59 (7.06-8.17)
Cholangitis4.22 (3.71-4.81)
Pruritus1.42 (1.22-1.66)
SEER historic stage
Localized1.00 (REF)
Regional1.01 (0.89-1.14)
Distant0.52 (0.46-0.58)
Unstaged0.85 (0.73-1.00)
Cancer directed therapies1
Chemotherapy1.39 (1.28-1.51)
Radiation1.21 (1.11-1.33)
Surgery0.82 (0.73-0.92)